Tech Company Financing Transactions
Nabriva Therapeutics Funding Round
On 4/13/2015, Nabriva Therapeutics announced $120 million in Series B investment from OrbiMed, Vivo Capital and EcoR1 Capital Management.
Transaction Overview
Company Name
Announced On
4/13/2015
Transaction Type
Venture Equity
Amount
$120,000,000
Round
Series B
Investors
OrbiMed (Lead Investor) (Chau Khuong)
Vivo Capital (Lead Investor) (Chen Yu)
Proceeds Purpose
The initial tranche of $50 million will enable Nabriva to progress its lead product, lefamulin, into clinical phase 3 studies in community-acquired bacterial pneumonia (CABP) and to continue the development of its product pipeline.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1000 Continental Dr. 600
King of Prussia, PA 19406
USA
King of Prussia, PA 19406
USA
Phone
Website
Email Address
Overview
Nabriva Therapeutics (Nasdaq: NBRV) is a biotechnology company focused on developing a new class of antibiotics, pleuromutilins, for the treatment of patients with serious infections caused by multi-drug resistant pathogens.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Colin Broom
Chief Financial Officer
Gary Sender
Chief Medical Officer
Jennifer Schranz
VP - Bus. Development
Steven Gelone
VP - General Counsel
Robert Crotty
Browse more venture capital transactions:
Prev: 4/13/2015: VacationFutures venture capital transaction
Next: 4/13/2015: Voyager Therapeutics venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC transactions on this site are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs